Sistematski pregled / meta-analiza 2022
Dijabetes i metabolizam

Dijeta s niskim udjelom ugljikohidrata u odnosu na uravnoteženu dijetu za smanjenje tjelesne težine i kardiovaskularnog rizika.

The Cochrane database of systematic reviews

Bosanski prijevod

Sažetak istraživanja

Pozadina Debate o efikasnim i sigurnim dijetama za upravljanje gojaznošću kod odraslih su u toku. Dijeta s niskim udjelom ugljikohidrata (također poznata kao 'dijeta s niskim udjelom ugljikohidrata') i dalje se naširoko promovira, reklamira i komercijalizira kao učinkovitija za mršavljenje i zdravija od 'uravnoteženih' dijeta za smanjenje težine sa ugljikohidratima.

Ciljevi Usporediti efekte dijeta s niskim udjelom ugljikohidrata za smanjenje tjelesne težine sa dijetama za smanjenje tjelesne težine s uravnoteženim rasponom ugljikohidrata, u odnosu na promjene u težini i kardiovaskularnom riziku, kod gojaznih i gojaznih odraslih osoba bez i sa dijabetes melitusom tipa 2 (T2DM).

Metode pretraživanja Pretražili smo MEDLINE (PubMed), Embase (Ovid), Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science Core Collection (Clarivate Analytics), ClinicalTrials. gov i Međunarodna platforma registra kliničkih ispitivanja SZO (ICTRP) do 25. juna 2021. i pregledane referentne liste uključenih ispitivanja i relevantnih sistematskih pregleda. Nisu primijenjena ograničenja jezika ili objavljivanja. Kriterijumi odabira Uključili smo randomizirane kontrolirane studije (RCT) kod odraslih (18+ godina) koji su imali prekomjernu težinu ili žive s gojaznošću, bez ili sa T2DM, i bez ili sa kardiovaskularnim stanjima ili faktorima rizika. Ispitivanja su morala upoređivati ​​dijetu s niskim udjelom ugljikohidrata s dijetama za smanjenje tjelesne težine s uravnoteženim ugljikohidratima (45% do 65% ukupne energije (TE)), imati fazu smanjenja težine od 2 sedmice ili duže i biti eksplicitno implementirana u primarnu svrhu smanjenja težine, sa ili bez savjeta za ograničavanje unosa energije. PRIKUPLJANJE I ANALIZA PODATAKA: Dva autora recenzije su nezavisno pregledala naslove i sažetke i članke u punom tekstu kako bi utvrdili podobnost; i nezavisno ekstrahovane podatke, procijenili rizik od pristranosti koristeći RoB 2 i procijenili sigurnost dokaza koristeći GRADE. Stratifikovali smo analize prema učesnicima bez i sa T2DM, te po dijetama samo sa fazama smanjenja težine i onima sa fazama smanjenja težine nakon kojih slijede faze održavanja težine. Primarni ishodi bili su promjena tjelesne težine (kg) i broj učesnika po grupi sa gubitkom težine od najmanje 5%, procijenjeno na kratko (tri mjeseca do glavnih rezultata Uključili smo 61 RCT s paralelnim kracima koji su randomizirali 6925 učesnika na bilo nisko-ugljikohidratne ili uravnotežene ugljikohidrate za smanjenje tjelesne težine = dijeta = dijeta sa visokim udjelom ugljikohidrata. Većina učesnika je sprovedena u Kini. 5118 randomiziranih) nije imalo T2DM Srednja početna težina je bila 95 kg (raspon od 66 do 132 kg). Samo 16/19 žena) i ljudi bez početnih kardiovaskularnih stanja, faktora rizika ili događaja (36/61) i holesterola niske gustine (LDL) u svim studijama Većina studija je ispitivala dijete sa niskim udjelom ugljikohidrata (> 50 g do 150 g dnevno ili 20% TE) u odnosu na kontrolnu dijetu uravnoteženu za tri makronutrijenta (24/61). U većini studija (45/61) energetski recept ili pristup korišten za ograničavanje unosa energije bio je sličan u obje grupe. Procijenili smo ukupan rizik od pristrasnosti ishoda u ispitivanjima kao pretežno visok, uglavnom zbog pristrasnosti zbog nedostajućih podataka o ishodima. Koristeći GRADE, procijenili smo sigurnost dokaza kao umjerenu do vrlo nisku u svim ishodima. Učesnici bez i sa T2DM izgubili su na težini kada su slijedili faze smanjenja težine obje dijeta na kratko (raspon: 12,2 do 0,33 kg) i dugoročno (raspon: 13,1 do 1,7 kg). Kod gojaznih i gojaznih učesnika bez T2DM: dijeta sa malo ugljenih hidrata za smanjenje telesne težine u poređenju sa dijetama za smanjenje telesne težine sa balansiranim ugljenim hidratima (samo faze smanjenja telesne težine) verovatno rezultiraju malom ili nikakvom razlikom u promeni telesne težine tokom tri do 8,5 meseci (srednja razlika (MD) -1,07 kg, (95% CI) -1.5% pouzdanosti -1. 2 = 51%, 3286 učesnika, 37 RCT, dokazi umjerene sigurnosti) i tokom jedne do dvije godine (MD -0,93 kg, 95% CI -1,81 do -0,04, I 2 = 40%, 1805 učesnika, 14 RCTs, umjerena sigurnost kao i LDL dokazi kao i LDL-dokaz); Dokazi su vrlo nesigurni o tome da li postoji razlika u broju učesnika po grupi sa gubitkom težine od najmanje 5% u jednoj godini (omjer rizika (RR) 1,11, 95% CI 0,94 prema 1,31, I 2 = 17%, 137 učesnika, 2 RCT-a, vrlo niska izvjesnost prekomjerne tjelesne težine i TDM2). dijeta za smanjenje tjelesne težine u usporedbi s dijetama za smanjenje tjelesne težine s uravnoteženim unosom ugljikohidrata (samo faze smanjenja težine) vjerovatno rezultiraju malom ili nikakvom razlikom u promjeni tjelesne težine tokom tri do šest mjeseci (MD -1,26 kg, 95% CI -2,44 do -0,09, I 2 = 47%, 1114 RCT ispitanici, 114-godišnji RCT dokazi, jedan do dvije godine). (MD -0,33 kg, 95% CI -2,13 do 1,46, I 2 = 10%, 813 učesnika, 7 RCT-a, dokazi umjerene sigurnosti, kao i u promjeni DBP, HbA1c i LDL holesterola u periodu od 1 do 2 godine. u jednoj do dvije godine (RR 0,90, 95% CI 0,68 do 1,20, I 2 = 0%, 106 učesnika, 2 RCT-a, dokazi o štetnim efektima koje su prijavili sudionici su bili ograničeni i nismo mogli izvući nikakve zaključke o ovim AUTORIMA i vjerojatno nema razlike u težini NCLU). faktori rizika do dvije godine praćenja, kada su gojazni i gojazni sudionici bez i sa T2DM randomizirani na dijetu s niskim udjelom ugljikohidrata ili dijetom za smanjenje tjelesne težine.

Prikaži originalni naslov i sažetak na engleskom

Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk.

Background Debates on effective and safe diets for managing obesity in adults are ongoing. Low-carbohydrate weight-reducing diets (also known as 'low-carb diets') continue to be widely promoted, marketed and commercialised as being more effective for weight loss, and healthier, than 'balanced'-carbohydrate weight-reducing diets.

Objectives To compare the effects of low-carbohydrate weight-reducing diets to weight-reducing diets with balanced ranges of carbohydrates, in relation to changes in weight and cardiovascular risk, in overweight and obese adults without and with type 2 diabetes mellitus (T2DM). Search methods We searched MEDLINE (PubMed), Embase (Ovid), the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science Core Collection (Clarivate Analytics), ClinicalTrials.gov and WHO International Clinical Trials Registry Platform (ICTRP) up to 25 June 2021, and screened reference lists of included trials and relevant systematic reviews. Language or publication restrictions were not applied. Selection criteria We included randomised controlled trials (RCTs) in adults (18 years+) who were overweight or living with obesity, without or with T2DM, and without or with cardiovascular conditions or risk factors. Trials had to compare low-carbohydrate weight-reducing diets to balanced-carbohydrate (45% to 65% of total energy (TE)) weight-reducing diets, have a weight-reducing phase of 2 weeks or longer and be explicitly implemented for the primary purpose of reducing weight, with or without advice to restrict energy intake. DATA COLLECTION AND ANALYSIS: Two review authors independently screened titles and abstracts and full-text articles to determine eligibility; and independently extracted data, assessed risk of bias using RoB 2 and assessed the certainty of the evidence using GRADE. We stratified analyses by participants without and with T2DM, and by diets with weight-reducing phases only and those with weight-reducing phases followed by weight-maintenance phases. Primary outcomes were change in body weight (kg) and the number of participants per group with weight loss of at least 5%, assessed at short- (three months to Main results We included 61 parallel-arm RCTs that randomised 6925 participants to either low-carbohydrate or balanced-carbohydrate weight-reducing diets. All trials were conducted in high-income countries except for one in China. Most participants (n = 5118 randomised) did not have T2DM. Mean baseline weight across trials was 95 kg (range 66 to 132 kg). Participants with T2DM were older (mean 57 years, range 50 to 65) than those without T2DM (mean 45 years, range 22 to 62). Most trials included men and women (42/61; 3/19 men only; 16/19 women only), and people without baseline cardiovascular conditions, risk factors or events (36/61). Mean baseline diastolic blood pressure (DBP) and low-density lipoprotein (LDL) cholesterol across trials were within normal ranges. The longest weight-reducing phase of diets was two years in participants without and with T2DM. Evidence from studies with weight-reducing phases followed by weight-maintenance phases was limited. Most trials investigated low-carbohydrate diets (> 50 g to 150 g per day or 20% of TE) treatment diets versus control diets balanced for the three macronutrients (24/61). In most trials (45/61) the energy prescription or approach used to restrict energy intake was similar in both groups. We assessed the overall risk of bias of outcomes across trials as predominantly high, mostly from bias due to missing outcome data. Using GRADE, we assessed the certainty of evidence as moderate to very low across outcomes. Participants without and with T2DM lost weight when following weight-reducing phases of both diets at the short (range: 12.2 to 0.33 kg) and long term (range: 13.1 to 1.7 kg). In overweight and obese participants without T2DM: low-carbohydrate weight-reducing diets compared to balanced-carbohydrate weight-reducing diets (weight-reducing phases only) probably result in little to no difference in change in body weight over three to 8.5 months (mean difference (MD) -1.07 kg, (95% confidence interval (CI) -1.55 to -0.59, I 2 = 51%, 3286 participants, 37 RCTs, moderate-certainty evidence) and over one to two years (MD -0.93 kg, 95% CI -1.81 to -0.04, I 2 = 40%, 1805 participants, 14 RCTs, moderate-certainty evidence); as well as change in DBP and LDL cholesterol over one to two years. The evidence is very uncertain about whether there is a difference in the number of participants per group with weight loss of at least 5% at one year (risk ratio (RR) 1.11, 95% CI 0.94 to 1.31, I 2 = 17%, 137 participants, 2 RCTs, very low-certainty evidence). In overweight and obese participants with T2DM: low-carbohydrate weight-reducing diets compared to balanced-carbohydrate weight-reducing diets (weight-reducing phases only) probably result in little to no difference in change in body weight over three to six months (MD -1.26 kg, 95% CI -2.44 to -0.09, I 2 = 47%, 1114 participants, 14 RCTs, moderate-certainty evidence) and over one to two years (MD -0.33 kg, 95% CI -2.13 to 1.46, I 2 = 10%, 813 participants, 7 RCTs, moderate-certainty evidence); as well in change in DBP, HbA1c and LDL cholesterol over 1 to 2 years. The evidence is very uncertain about whether there is a difference in the number of participants per group with weight loss of at least 5% at one to two years (RR 0.90, 95% CI 0.68 to 1.20, I 2 = 0%, 106 participants, 2 RCTs, very low-certainty evidence). Evidence on participant-reported adverse effects was limited, and we could not draw any conclusions about these. AUTHORS' CONCLUSIONS: There is probably little to no difference in weight reduction and changes in cardiovascular risk factors up to two years' follow-up, when overweight and obese participants without and with T2DM are randomised to either low-carbohydrate or balanced-carbohydrate weight-reducing diets.

Autorstvo i publikacija

Autori

Naude CE, Brand A, Schoonees A, Nguyen KA, Chaplin M, Volmink J.

Časopis
The Cochrane database of systematic reviews
Vrste publikacije
Istraživačka podrška vlade izvan SAD-a, Sistematski pregled, Sistematski pregled, Članak u časopisu
Licenca
CC BY-NC
Citiranja u Europe PMC
46
Provjerljivi identifikatori

Izvorni podaci

DOI
10.1002/14651858.cd013334.pub2
PMID
35088407
PMCID
PMC8795871
Provjereno
2026-07-26
Otvori cijeli rad u Europe PMC
Napomena o bosanskom prijevodu

Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.

Pregledaj originalni članak na engleskom
Istraživački zapis služi za informiranje i istraživanje. Ne zamjenjuje medicinski savjet, dijagnozu ili preporuku liječenja.